These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 38441191)

  • 1. High dietary iodine intake may contribute to the low death rate from COVID-19 infection in Japan with activation by the lactoperoxidase system.
    Smith ML; Sharma S; Singh TP
    Scand J Immunol; 2023 Jul; 98(1):e13269. PubMed ID: 38441191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comments on the Discussion Forum: Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS-CoV-2 infection.
    Smith ML; Sharma S; Singh TP
    Scand J Immunol; 2022 Feb; 95(2):e13111. PubMed ID: 34709678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Genome Epidemiological Study of SARS-CoV-2 Introduction into Japan.
    Sekizuka T; Itokawa K; Hashino M; Kawano-Sugaya T; Tanaka R; Yatsu K; Ohnishi A; Goto K; Tsukagoshi H; Ehara H; Sadamasu K; Taira M; Shibata S; Nomoto R; Hiroi S; Toho M; Shimada T; Matsui T; Sunagawa T; Kamiya H; Yahata Y; Yamagishi T; Suzuki M; Wakita T; Kuroda M
    mSphere; 2020 Nov; 5(6):. PubMed ID: 33177213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.
    Yamayoshi S; Iwatsuki-Horimoto K; Okuda M; Ujie M; Yasuhara A; Murakami J; Duong C; Hamabata T; Ito M; Chiba S; Kobayashi R; Takahashi S; Mitamura K; Hagihara M; Shibata A; Uwamino Y; Hasegawa N; Ebina T; Izumi A; Kato H; Nakajima H; Sugaya N; Seki Y; Iqbal A; Kamimaki I; Yamazaki M; Kawaoka Y; Furuse Y
    Emerg Infect Dis; 2022 Nov; 28(11):2198-2205. PubMed ID: 36198306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.
    Yamayoshi S; Nagai E; Mitamura K; Hagihara M; Kobayashi R; Takahashi S; Shibata A; Uwamino Y; Hasegawa N; Iqbal A; Kamimaki I; Iwatsuki-Horimoto K; Nagamura-Inoue T; Kawaoka Y
    Epidemiol Infect; 2024 Jan; 152():e24. PubMed ID: 38258464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The First Pediatric Patients with Coronavirus Disease 2019 (COVID-19) in Japan: Risk of Co-Infection with Other Respiratory Viruses.
    Kakuya F; Okubo H; Fujiyasu H; Wakabayashi I; Syouji M; Kinebuchi T
    Jpn J Infect Dis; 2020 Sep; 73(5):377-380. PubMed ID: 32475878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resurgence of Respiratory Syncytial Virus Infections during COVID-19 Pandemic, Tokyo, Japan.
    Ujiie M; Tsuzuki S; Nakamoto T; Iwamoto N
    Emerg Infect Dis; 2021 Nov; 27(11):2969-2970. PubMed ID: 34388086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodide supplementation of the anti-viral duox-lactoperoxidase activity may prevent some SARS-CoV-2 infections.
    Smith ML; Sharma S; Singh TP
    Eur J Clin Nutr; 2022 Apr; 76(4):629-630. PubMed ID: 34471253
    [No Abstract]   [Full Text] [Related]  

  • 15. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.
    Abela IA; Schwarzmüller M; Ulyte A; Radtke T; Haile SR; Ammann P; Raineri A; Rueegg S; Epp S; Berger C; Böni J; Manrique A; Audigé A; Huber M; Schreiber PW; Scheier T; Fehr J; Weber J; Rusert P; Günthard HF; Kouyos RD; Puhan MA; Kriemler S; Trkola A; Pasin C
    mBio; 2024 Feb; 15(2):e0272223. PubMed ID: 38270455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multisystem Inflammatory Syndrome in Adults after Mild SARS-CoV-2 Infection, Japan.
    Yamada Y; Fujinami K; Eguchi T; Takefuji H; Mori N
    Emerg Infect Dis; 2021 Jun; 27(6):1740-1742. PubMed ID: 33821784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of iodine complex in SARS-CoV-2-infected patients with mild to moderate symptoms: study protocol for a randomized controlled trial.
    Ashraf S; Ashraf S; Ashraf M; Farooq I; Akmal R; Imran MA; Kalsoom L; Ashraf S; Rafique S; Ghufran M; Akram MK; Sohaib-Ur-Rehman ; Nadeem MF; Matti N; Siddiqui UN; Humayun A; Saboor QA; Ahmad A; Ashraf M; Izhar M;
    Trials; 2022 Jan; 23(1):58. PubMed ID: 35045888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical care of newborns born to mothers with confirmed or suspected severe acute respiratory syndrome coronavirus 2 infections in Japan.
    Morioka I; Toishi S; Kusaka T; Wada K; Mizuno K;
    Pediatr Int; 2022 Jan; 64(1):e14855. PubMed ID: 34041810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Variants and Age-Dependent Infection Rates among Household and Nonhousehold Contacts.
    Miyahara R; Tamura K; Kato T; Nakazaki M; Otani K; Ko YK; Kamigaki T; Arima Y; Tani H; Oishi K; Suzuki M
    Emerg Infect Dis; 2023 Aug; 29(8):1648-1650. PubMed ID: 37343546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Incubation Period during Omicron BA.5-Dominant Period, Japan.
    Cheng HY; Akhmetzhanov AR; Dushoff J
    Emerg Infect Dis; 2024 Jan; 30(1):206-207. PubMed ID: 38146985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.